Clinical and experimental dermatology · 2024
Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Megna Matteo, Ruggiero Angelo, Torta Ginevra, Martora Fabrizio, Bianco Mariateresa, Potestio Luca
Аннотация
BACKGROUND: Bimekizumab is the latest monoclonal antibody approved for the management of moderate-to-severe plaque psoriasis. Currently, data investigating its use in real-world settings are limited.
OBJECTIVES: To assess the efficacy and safety of bimekizumab, also comparing patients who are biologic-naive vs. biologic-experienced.
METHODS: A short-term (16 weeks) real-world monocentric prospective study was undertaken.
RESULTS: Globally, 56 patients were included. At baseline, mean Psoriasis Activity Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were 16.9 (SD 7.8) and 22.6 (SD 5.9), respectively. A ≥ 75%/≥ 90%/100% reduction in PASI (PASI 75/90/100) were reached by 77% (43/56)/50% (28/56)/43% (43/56) of patients at week 4 and by 88% (49/56)/82% (46/56)/70% (39/56) of patients at week 16. In our cohort of 56 people, 29 (52%) patients were biologic-naive whereas 27 (48%) were biologic-experienced. At baseline, both PASI and DLQI were significantly higher in the biologic-naive group compared with the biologic-experienced group [PASI 19.4 (SD 7.7) vs. 14.2 (SD 7.0), P < 0.05; DLQI: 25.3 (SD 4.5) vs. 19.7 (SD 6.0), P < 0.001]. Although not significant, a higher percentage of patients in the biologic-naive group compared with the biologic-experienced group reached PASI 75 (79% vs. 63%, P = 0.18), PASI 90 (62% vs. 44%, P = 0.19) and PASI 100 (48% vs. 37%, P = 0.40) at week 4. However, the percentage of PASI 75/90/100 response were similar between the two groups at week 16. Regarding safety, three candidiasis (5%) and one (2%) eczematous reaction were reported, without differences between the two groups. Finally, two (4%) bimekizumab discontinuation because of treatment failure and three (5%) for AEs were collected.
CONCLUSIONS: Our study confirmed the efficacy and safety of bimekizumab, suggesting that the previous failure of biologics does not seem to affect its therapeutic effectiveness.
OBJECTIVES: To assess the efficacy and safety of bimekizumab, also comparing patients who are biologic-naive vs. biologic-experienced.
METHODS: A short-term (16 weeks) real-world monocentric prospective study was undertaken.
RESULTS: Globally, 56 patients were included. At baseline, mean Psoriasis Activity Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were 16.9 (SD 7.8) and 22.6 (SD 5.9), respectively. A ≥ 75%/≥ 90%/100% reduction in PASI (PASI 75/90/100) were reached by 77% (43/56)/50% (28/56)/43% (43/56) of patients at week 4 and by 88% (49/56)/82% (46/56)/70% (39/56) of patients at week 16. In our cohort of 56 people, 29 (52%) patients were biologic-naive whereas 27 (48%) were biologic-experienced. At baseline, both PASI and DLQI were significantly higher in the biologic-naive group compared with the biologic-experienced group [PASI 19.4 (SD 7.7) vs. 14.2 (SD 7.0), P < 0.05; DLQI: 25.3 (SD 4.5) vs. 19.7 (SD 6.0), P < 0.001]. Although not significant, a higher percentage of patients in the biologic-naive group compared with the biologic-experienced group reached PASI 75 (79% vs. 63%, P = 0.18), PASI 90 (62% vs. 44%, P = 0.19) and PASI 100 (48% vs. 37%, P = 0.40) at week 4. However, the percentage of PASI 75/90/100 response were similar between the two groups at week 16. Regarding safety, three candidiasis (5%) and one (2%) eczematous reaction were reported, without differences between the two groups. Finally, two (4%) bimekizumab discontinuation because of treatment failure and three (5%) for AEs were collected.
CONCLUSIONS: Our study confirmed the efficacy and safety of bimekizumab, suggesting that the previous failure of biologics does not seem to affect its therapeutic effectiveness.